| Primary | Percent Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 | The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth by adding the percentage hair loss in the various areas (i.e. top, back, each side) of the scalp. The primary efficacy variable was the percent change from baseline in SALT score at Week 24. This was calculated as the mean of the changes from Baseline (Visit 2) SALT score to Week 24 (Visit 10) SALT score, divided by Baseline SALT score and expressed as a percentage. | This primary analysis utilized the SALT score with imputation for last observation carried forward (LOCF) and was based on the intent-to-treat population. | Posted | | Mean | Standard Deviation | percent | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID Dosing | ATI-501 400mg BID dosing (low dose) - oral administration ATI-501 Low dose: ATI-501 oral low dose | | OG001 | ATI-501 600mg BID Dosing | ATI-501 600mg BID dosing (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID Dosing | ATI-501 800mg BID dosing (high dose) - oral administration ATI-501 high dose for oral administration | | OG003 | Placebo | Placebo - oral administration |
| | Units | Counts |
|---|
| Participants | - OG00023
- OG00123
- OG00222
- OG003
|
| | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000-25.6± 39.75
- OG001-30.4± 41.23
- OG002-25.9± 29.86
- OG003
|
|
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| The planned sample size is approximately 95 enrolled subjects with approximately 45 subjects enrolled with AT or AU. Because the primary efficacy analysis of mean percent reduction in hair loss using SALT scores is expected to be more sensitive than the SALT50 responder analysis, the power for the primary analysis is also expected to be no less than 80%. | Mixed Models Analysis | | 0.011 | All statistical testing was two-sided and performed using a significance (alpha) level of 0.05. | Mean Difference (Net) | -19.26 | Standard Error of the Mean | 5.020 | 2-Sided | 95 | -33.98 | -4.54 | | | | | |
|
| Secondary | Percent Change From Baseline in the Alopecia Density and Extent Score (ALODEX) at Week 24 | The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth. | Intent-to-treat population using LOCF to address missing data. | Posted | | Least Squares Mean | Standard Error | percent | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID Dosing | ATI-501 400mg BID Dosing (low dose) - oral administration ATI-501 Low dose: ATI-501 oral low dose | | OG001 | ATI-501 600mg BID Dosing | ATI-501 600mg BID Dosing (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID Dosing | ATI-501 800mg BID Dosing (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Mean Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 | The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth by adding the percentage hair loss in the various areas (i.e. top, back, each side) of the scalp. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID Dosing (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo | |
|
| Secondary | Mean Change From Baseline in the Alopecia Density and Extent (ALODEX) Score at Week 24 | The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | |
|
| Secondary | Count of Subjects Achieving at Least a 50% Reduction in Alopecia Density and Extent (ALODEX) Score at Week 24 | The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | |
|
| Secondary | Count of Subjects in Each Treatment Arm Achieving at Least a 50% Reduction in Severity of Alopecia Tool (SALT) Score at Week 24 Compared to Baseline | The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth by adding the percentage hair loss in the various areas (i.e. top, back, each side) of the scalp. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome, Left Eyebrow | The Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome is the investigator's assessment of the subject's facial hair (eyebrow(s), eyelashes,and if male, beard) at a particular point in time. The investigator was instructed to NOT refer to any other assessments to assist with these assessments. The investigator or designee assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome, Right Eyebrow | The Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome is the investigator's assessment of the subject's facial hair (eyebrow(s), eyelashes,and if male, beard) at a particular point in time. The investigator was instructed to NOT refer to any other assessments to assist with these assessments. The investigator or designee assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome, Left Eyelash | The Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome is the investigator's assessment of the subject's facial hair (eyebrow(s), eyelashes,and if male, beard) at a particular point in time. The investigator was instructed to NOT refer to any other assessments to assist with these assessments. The investigator or designee assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome, Right Eyelash | The Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome is the investigator's assessment of the subject's facial hair (eyebrow(s), eyelashes,and if male, beard) at a particular point in time. The investigator was instructed to NOT refer to any other assessments to assist with these assessments. The investigator or designee assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome, Beard, Male Subjects | The Alopecia Facial Hair Appearance Assessment (AFHA)-Clinician Reported Outcome is the investigator's assessment of the subject's facial hair (eyebrow(s), eyelashes,and if male, beard) at a particular point in time. The investigator was instructed to NOT refer to any other assessments to assist with these assessments. The investigator or designee assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome, Left Eyebrow | The Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome is the patient's assessment of their facial hair (eyebrow(s), eyelashes, and if male, beard) at a particular point in time. The patient assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome, Right Eyebrow | The Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome is the patient's assessment of their facial hair (eyebrow(s), eyelashes, and if male, beard) at a particular point in time. The patient assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome, Right Eyelash | The Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome is the patient's assessment of their facial hair (eyebrow(s), eyelashes, and if male, beard) at a particular point in time. The patient assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose: ATI-501 oral low dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome, Left Eyelash | The Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome is the patient's assessment of their facial hair (eyebrow(s), eyelashes, and if male, beard) at a particular point in time. The patient assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome, Beard, Male Subjects | The Alopecia Facial Hair Appearance Assessment (AFHA)-Patient Reported Outcome is the patient's assessment of their facial hair (eyebrow(s), eyelashes, and if male, beard) at a particular point in time. The patient assessed the affected facial hair areas (eyebrows, eyelashes and if male, beard) using a 5 point scale for each target area [1-Full (Target Area Hair); 2-Most (Target Area Hair); 3-Some (Target Area Hair); 4-A Little (Target Area Hair); 5-No (Target Area Hair)]. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in the Subject Global Impression of Severity (SGIS) at Week 24, Patchy Alopecia Areata | The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo |
|
| Secondary | Change From Baseline in the Subject Global Impression of Severity (SGIS) at Week 24, Alopecia Universalis or Alopecia Totalis | The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. One patient was excluded from the analysis based on the visit windowing conventions that was previously established. This patient's Week 24 SGIS occurred at Day 128, which is outside of the window for inclusion of results at Week 24. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in the Physician Global Impression of Severity (PhGIS) at Week 24, Patchy Alopecia Areata | The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 |
|
| Secondary | Change From Baseline in the Physician Global Impression of Severity (PhGIS) at Week 24, Alopecia Universalis or Alopecia Totalis | The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 |
|
| Secondary | Alopecia Impact Assessment (AIA) Patient Reported Outcome Change From Baseline at Week 24 | The Alopecia Impact Assessment (AIA) is a 13-item patient reported outcome questionnaire which measures the subject's experience with impacts related to alopecia (inclusive of all 3 subtypes observed on study) in managing appearance, worry, sadness, loss of confidence, self-consciousness, embarrassment, feeling unattractive, limitation of social activities, limitation of physical activities, unwanted attention, sweat in eyes, debris in eyes, and debris in nose. The AIA has a recall period of "over the past seven days". An 11-point NRS with anchors "0 - Not at all [impact]" and "10 - Extremely [impact]" (e.g., "Not at all bothersome" and "Extremely bothersome"; "Not at all worried" and "Extremely worried") is utilized. The AIA produces single-item (0-10) and mean total (0-10) scores, with higher scores indicating higher levels of impact. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 |
|
| Secondary | Subject Global Impression of Treatment Satisfaction (SGITS) at Week 24, Patchy Alopecia Areata | The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo | Placebo - oral administration |
|
| Secondary | Subject Global Impression of Treatment Satisfaction (SGITS) at Week 24, Alopecia Universalis or Alopecia Totalis | The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo | |
|
| Secondary | Change From Baseline in the Subject Global Satisfaction With Hair Quality (SGSHQ) for Entire Scalp at Week 24, Patchy Alopecia Areata | The investigator or study staff instructed the subject to answer the Subject Global Satisfaction with Hair Quality (SGSHQ) questionnaire in relation to their satisfaction with the quality of scalp hair at the time of questionnaire completion (ie "right now"). Subjects assessed their satisfaction with the quality of their scalp hair on a 7-point satisfaction scale from extremely satisfied to extremely dissatisfied at the visits. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in the Subject Global Satisfaction With Hair Quality (SGSHQ) for Entire Scalp at Week 24, Alopecia Universalis or Alopecia Totalis | The investigator or study staff instructed the subject to answer the Subject Global Satisfaction with Hair Quality (SGSHQ) questionnaire in relation to their satisfaction with the quality of scalp hair at the time of questionnaire completion (ie "right now"). Subjects assessed their satisfaction with the quality of their scalp hair on a 7-point satisfaction scale from extremely satisfied to extremely dissatisfied at the visits. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change in Dermatology Life Quality Index Total Score (DLQI) Between Baseline and Week 24 | The 10 question Dermatology Life Quality Index (DLQI) questionnaire was completed by subjects at Baseline, Week 4, Week 12, and Week 24. When completing the questionnaire, subjects were instructed to think of their hair loss in place of "skin problem" and "skin" as referenced in the questionnaire. Possible summary scores could range from 0 to 30 with higher scores indicating a worse outcome. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Mean | Standard Deviation | score on a scale | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose | | OG003 | Placebo | |
|
| Secondary | Subject Global Impression of Change (SGIC) at Week 24 | The Subject Global Impression of Change (SGIC) is a 7-point descriptive scale completed by subjects at Week 24 (Intent-to-treat population with reported data falling within the windowed Week 24 visit timeframe). Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the subject's overall impression of change for his/her alopecia during the treatment period. | Intent-to-treat population using Last Observation Carried Forward (LOCF) to address missing data. Per SAP, the allowed window days for Week 24 visit are 155-182. There were 4 patients in the 400mg group, 4 patients in the 600mg group, 3 patients in the 800mg group, and 5 patients in the placebo group who fell outside this window. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Physician Global Impression of Change (PhGIC) at Week 24 | The Physician Global Impression of Change (PhGIC) is a 7-point descriptive scale completed by investigators at Week 24 (Intent-to-treat population with reported data falling within the windowed Week 24 visit timeframe). Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the investigator's overall impression of change for the subject's alopecia during the treatment period. | Intent-to-treat population using Last Observation Carried Forward (LOCF) to address missing data. Per SAP, the allowed window days for Week 24 visit are 155-182. There were 4 patients in the 400mg group, 4 patients in the 600mg group, 3 patients in the 800mg group, and 5 patients in the placebo group who fell outside this window. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID | ATI-501 800mg BID (high dose) - oral administration ATI-501 high dose |
|
| Secondary | Change From Baseline in Alopecia Scalp Appearance Assessment (ASAA): Scalp-Clinician Reported Outcome for Target Patch, Patchy Alopecia Areata | The Scalp Clinician Reported Outcome for Target Patch provides the investigator's assessment for Patchy Alopecia Areata (AAP) patients regarding the appearance of the patient's target patch (identified by the patient as his or her most bothersome area of scalp hair loss at Baseline). The assessment was completed by investigators at Baseline, Week 2, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the patient's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose |
|
| Secondary | Change From Baseline in Alopecia Scalp Appearance Assessment (ASAA): Scalp-Clinician Reported Outcome for Entire Scalp, All Patients | The Scalp Clinician Reported Outcome for Entire Scalp was completed for patients with Patchy Alopecia Areata, Alopecia Universalis, and Alopecia Totalis and assesses the appearance of the patient's whole scalp. The assessment was completed by investigators at Baseline, Week 2, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the patient's whole scalp. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|
| Secondary | Change From Baseline in Alopecia Scalp Appearance Assessment (ASAA): Scalp-Patient Reported Outcome for Target Patch, Patchy Alopecia Areata | The Scalp Patient Reported Outcome for Target Patch was completed by patients with Patchy Alopecia Areata (AAP) and assesses the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline). The assessment was completed by AAP subjects at Baseline, Week 2, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | |
|
| Secondary | Change From Baseline in Alopecia Scalp Appearance Assessment (ASAA): Scalp-Patient Reported Outcome for Entire Scalp, All Patients | The Scalp Patient Reported Outcome for Entire Scalp was completed by patients with Patchy Alopecia Areata, Alopecia Universalis, and Alopecia Totalis and assesses the appearance of the patient's whole scalp. The assessment was completed by patients at Baseline, Week 2, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the patient's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points. | Intent-to-treat population using Last Observation Carried Forward to address missing data. | Posted | | Count of Participants | | Participants | | Baseline-Week 24 | | | | ID | Title | Description |
|---|
| OG000 | ATI-501 400mg BID | ATI-501 400mg BID (low dose) - oral administration ATI-501 Low dose | | OG001 | ATI-501 600mg BID | ATI-501 600mg BID (mid dose) - oral administration ATI-501 Mid dose | | OG002 | ATI-501 800mg BID |
|